Core Insights - The company has undergone a comprehensive rebranding from N2OFF, Inc. to Nexentis Technologies Inc., reflecting its evolution into an innovative data-driven biotech firm focused on mitochondrial biology and precision oncology [1][2][4] - The rebranding is part of a strategic pivot that includes the integration of MitoCareX Bio Ltd., which is now a wholly-owned subsidiary, enhancing the company's drug discovery capabilities [3][6] Company Overview - Nexentis Technologies Inc. is focused on developing a pipeline of first-in-class small-molecule programs targeting mitochondrial SLC25 carriers, with applications in oncology and inflammatory metabolic diseases [3][5] - The company also maintains investments in solar energy assets through a Ready to Build (RTB) business model, which are considered non-core assets [1][3] Strategic Developments - The acquisition of MitoCareX on October 20, 2025, marked a significant shift from cleantech to biotechnology, establishing a foundation for the company's drug discovery strategy [6] - MitoCareX has validated its MITOLINE discovery platform, generating in vitro data that demonstrates anti-tumor activity and potential anti-inflammatory benefits, with markets for these indications projected to exceed $120 billion by 2030 [6] Research and Development Focus - The company is advancing a precision oncology and inflammation pipeline, targeting hard-to-treat resistant cancers and metabolic-inflammatory diseases, with plans for preclinical candidate nominations [6]

Core Viewpoint - N2OFF, Inc. has successfully completed the merger with MitoCareX Bio Ltd., expanding its portfolio into the biotech sector focused on cancer therapeutics [1][3]. Company Overview - N2OFF is a cleantech company primarily engaged in solar energy assets using the RTB (Ready to Build) business model, currently leading four solar projects across three EU countries [5]. - MitoCareX specializes in drug discovery targeting cancer therapeutics through the mitochondrial SLC25 protein family, utilizing its proprietary algorithm MITOLINE for 3D comparative modeling [2]. Merger Details - The acquisition closed on October 20, 2025, with N2OFF purchasing ordinary shares of MitoCareX for $700,000 and acquiring the remaining shares, making MitoCareX a wholly-owned subsidiary [3]. - The agreement stipulates that the sellers will receive 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years, along with milestone-based issuances of up to 25% of N2OFF's common stock [3]. Market Potential - The Global Cancer Therapeutics and Biotherapeutics Market is projected to grow from $211.02 billion in 2025 to $378.62 billion by 2032, with a CAGR of 8.7% [2].